Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 121-132 , April 2010

Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract

  • Carlos Sostres, MD (Research Fellow)

      Affiliations

    • Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain
    • ,
  • Carla J. Gargallo, MD (Research Fellow)

      Affiliations

    • Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain
    • ,
  • Maria T. Arroyo, MD, DSc (Permanet Staff Member)

      Affiliations

    • Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain
    • CIBERehd, Aragon Health Sciences Institute, Zaragoza, Spain
    • ,
  • Angel Lanas, MD, DSc (Professor, Clinical Chief)

      Affiliations

    • Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain
    • CIBERehd, Aragon Health Sciences Institute, Zaragoza, Spain
    • University of Zaragoza, Spain
    • Corresponding Author InformationCorresponding author. Servicio de Aparato Digestivo, Hospital Clínico Universitário Lozano Blesa, c/Domingo Miral s/n, 5009 Zaragoza, Spain.

References 

  1. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med. 2001;110:4S–7S
  2. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol. 2006;101:2128–2138
  3. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med. 1989;86:449–458
  4. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am. 1996;25:279–298
  5. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23:163–173
  6. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol. 2005 Sept;56(Suppl. 5):5–31Review
  7. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000;119:706–714
  8. Lanas A, García Rodriguez LA, Polo-Tomas M, Ponce M, Alonso-Abreu I, Perez Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009 Jul;104(7):1633–1641
  9. Brun J, Jones R. Non-steroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med. 2001;110:12S–13S
  10. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28:527–532
  11. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82:1153–1158
  12. Lanas A, Hunt R. Prevention of anti-inflammatory drug induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med. 2006;38:415–428
  13. Silverstein FE, Graham DY, Senior JR, Davies HW, Sttruthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241–249
  14. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528
  15. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc. 2000;284:1247–1255
  16. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665–674
  17. Tannenbaum H, Bombardier C, Davis P, Russell AS, Third Canadian Consensus Conference Group . An evidence based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol. 2006;33:140–157Erratum in: J Rheumatol. 2006;33:829 and J Rheumatol. 2006;33:440
  18. De Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1
  19. Lanas A, García Rodriguez L-A, Arroyo MT, Gomollon F, Feu F, Gonzalez-Pérez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut. 2006 Dec;55(12):1731–1738
  20. Ramsoekh D, Van Leerdam ME, Rauws EAJ, Tygat GN. Outcome of peptic ulcer bleeding, nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2005;3:859–864
  21. Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, et al A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 2005;100:1685–1693
  22. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective. J Rheumatol. 1998;25:8–16
  23. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B, et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004;50(8):2433–2440
  24. Pérez-Aisa MA, Del Pino D, Siles M, Lanas A. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;21:65–67
  25. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol. 2007;102:1101–1107
  26. Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after de introduction of the proton pump inhibitors, a study of the Swedish population from 1974–2002. BMC Gastroenterol. 2009 Apr 20;9:25
  27. Sung J, Kuipers E, El-Serag H. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009 May 1;29(9):938–946
  28. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in the Netherland. Aliment Pharmacol Ther. 2006;23:1587–1593
  29. Kang JY, Elders A, Majeed A, Maxwell JD, Bardhan KD. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982–2002. Aliment Pharmacol Ther. 2006;24:65–79
  30. Zhao Y, Encinosa W. Hospitalizations for gastrointestinal bleeding in 1998 and 2006. Healthcare cost and utilization project. 2008 Dec.
  31. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644–R665
  32. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119:255–266
  33. Skelly MM, Hawkey CJ. Dual COX inhibition and upper gastrointestinal damage. Curr Pharm Des. 2003;9:2191–2195
  34. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127:395–402
  35. Rahme E, Dasgupta K, Toubouti Y, Barkoun AN, Bardou M. GI effect of rofecoxib and celecoxib versus NSAID in patients on low dose aspirin, a population-based retrospective cohort study. Gastroenterology. 2004;126
  36. Lanas A, Garcia-Rodriguez LA, Arroyo MA, Gomollón F, Zapata E, Bujanda L, et al. Coxibs, NSAIDs, aspirin, PPIs and the risks of upper GI bleeding in common clinical practice. Gastroenterology. 2005;128:629
  37. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Adenomatous polyp prevention on Vioxx (APPROVe) trial investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–1102
  38. Solomon SD, Mc Murray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Adenoma Prevention with Celecoxib (APC) study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071–1080
  39. Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Health Care Pat Saf. 2009;1:1–25
  40. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Pre-SAP Trial Investigators. Celecoxib for de prevention of colorectal adenomatous polyps. N Engl J Med. 2006 Aug 31;355(9):885–895
  41. McHippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366
  42. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006 Mar 13;
  43. Mc Gettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and non selective inhibitors of cyclooxygenase 2. J Am Med Assoc. 2006 Oct 4;296(13):1633–1644
  44. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomized comparison. Lancet. 2006 Nov 18;368(9549):1771–1781
  45. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomized comparison. Lancet. 2007 Feb 10;369(9560):465–473
  46. Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res Ther. 2008;10(Suppl. 2):S4
  47. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res Ther. 2008;10(Suppl. 2):S3
  48. Hawkey CJ, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U, et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut. 2003 Nov;52(11):1537–1542
  49. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009 Sep 15;104(6):840–845
  50. Lanas A, Fuentes J, Benito R, Bajador E, Serrano P, Sainz R. Helicobacter pylori increases the risk of gastrointestinal bleeding in patients taking low dose aspirin. Gastroenterology. 2000;118:A252
  51. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al. Sratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002 Oct;123(4):1006–1012
  52. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994 Apr 30;343:1075–1078
  53. Huang JQ, Sridhar L, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22
  54. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967–973
  55. Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol. 2008;103:323–332
  56. Johnson DA. Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist. Rev Cardiovasc Med. 2005;6(Suppl. 4):S15–S22
  57. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:1–111(CD002296)
  58. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329(7472):948–957
  59. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): A phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009 Jul 11;374(9684):119–125
  60. Canadian Coordinating Office for Health Technology Assessment . Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2004 Feb;Report No.: 12
  61. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002 Jan 28;162(2):169–175
  62. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002 Jun 27;346(26):2033–2038
  63. Chan F, Ching JY, Hung LC, Wong VW, Leung VK, Kung NM, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005 Jan 20;352(3):238–244
  64. Lanas A, García-Rodriguez LA, Arroyo MT, Bujanda L, Gomollon F, Forné M, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007 Mar;102(3):507–515
  65. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. J Am Med Assoc. 2004 Oct 27;292(16):1955–1960
  66. Ho PM, Maddox T, Wang l, Finhn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J Am Med Assoc. 2009;301(9):937–944
  67. Laine L. Proton pump inhibitors and bone fractures?. Am J Gastroenterol. 2009 Mar;104(2 Suppl.):S21–S26
  68. Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther. 2003 Jan;17(2):201–210
  69. Chan FK, Hung LC, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002 Dec 26;347(26):2104–2110
  70. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118(11):1271–1278
  71. Lanas A, Martin-Mola E, Ponce J, Navarro F, Pique JM, Blanco FJ. Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents. Gastroenterol Hepatol. 2003;26(8):485–502
  72. Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther. 2004;20(3):321–331
  73. Chan FKL, Wong VW, Suen BY, Wu JC, Leung WH, Le YT, et al. Proton pump inhibitor plus a COX-2 selective inhibitors for the prevention of recurrent ulcer bleeding in patients with arthritis. A double blind, randomized trial. Gastroenterology. 2006;130:133;(A732)
  74. Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG, et al. Cost effectiveness of COX-2 selective inhibitors and traditional NSAIDs or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ. 2009 Jul 14;339:b2538
  75. Sturkenboom MCJM, Burke TA, Tangelder MJD, et al. Adherence to proton pump of inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003;18:1137–1147
  76. Van Soest E, Sturkenboom MCJM, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007 Jul 15;26(2):265–275
  77. Abraham NS, El-Serag HB, Johnson ML, Hartman C, Richardson P, Ray WA, et al. National adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs. Gastroenterology. 2005;126:1171–1178
  78. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;5(359):9–13
  79. Hawkey CJ, Tulassay Z, Szczepanski L, Van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. [see comments] [published erratum appears in Lancet 1998;352:1634] Lancet. 1998;352:1016–1021Comment in: Lancet 1998;352:1001–3
  80. Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Langstrom G, et al Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol. 2005;100(5):1028–1036
  81. Yeomans ND, Lanas A, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22(9):795–801
  82. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998 Mar 12;338(11):719–726
  83. Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998;12:135–140
  84. Lai K, Hui W, Wong B, Hu W, Chan O, Lam S. Lansoprazole but not rofecoxib reduced dyspeptic symptoms of patients on NSAIDS. Gastroenterology. 2005;128:137A
  85. Lanas A. Review article: recommendations for the clinical management of patients taking non-steroidal anti-inflammatory drugs: a gastroenterologist's perspective. Aliment Pharmacol Ther. 2005;1:16–19

PII: S1521-6918(09)00158-9

doi: 10.1016/j.bpg.2009.11.005

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 121-132 , April 2010

Article Tools

* Image Usage & Resolution